Veran Launches New Navigated Catheter to Help Physicians Diagnose and Guide Treatment of Smaller, Early-stage Lung Cancer Lesions

Veran Medical is officially launching their new SPiN Access Catheter™, an extended working channel navigated by an Always-On Tip Tracked® guidewire. The SPiN Access Catheter™ provides lung specialists a catheter-based approach they are familiar with, but with the added advantages of a more accurate 3D map for navigation, respiratory gating, and compatibility with Always-On Tip Tracked® sampling instruments. This new catheter enables more accurate 3D navigation without the need for intraprocedural fluoroscopy during sampling.

The first ever procedures with the new SPiN Access Catheter™ were completed on October 4th by Dr. Sandeep Bansal, an Interventional Pulmonologist at Penn Highlands Healthcare in Dubois, PA. “The SPiN Access Catheter™ is a game changer as it provides me with an extended working channel approach but with Veran’s added benefits of more accurate navigation, the ability to track respiration, tip tracked sampling instruments, and the ability to transition to a navigated TTNA, when needed,” said Dr. Sandeep Bansal. “This will help us to diagnose lung cancer earlier, and will therefore ultimately help save lives.”

“The expanding adoption of lung cancer screening has given us a real opportunity to catch cancer earlier and save lives, but only if we can help physicians reach the smallest nodules,” said Veran Medical CEO Jason Pesterfield. “Our new software applications and SPiN Access Catheter™ provide additional flexibility to help physicians reach and guide treatment for early stage cancer when patients have the best prognosis.”

Veran’s next generation SPiN Thoracic Navigation System™ offers an industry leading precision thoracic guidance platform that allows lung specialists to seamlessly transition between a navigated endobronchial approach and a navigated transthoracic approach utilizing SPiN Perc™, to help physicians diagnose lung cancer earlier. A published clinical study utilizing a multi-modality approach, including Veran’s SPiN System™ and SPiN Perc™, have demonstrated a 92% diagnostic yield.

Lung Cancer remains the number one cancer killer worldwide. 94 million current or former smokers remain at elevated risk in the U.S. alone. More than 8 million people in the U.S. currently meet the criteria for lung cancer screening. When suspicious lesions are discovered, patients need answers. But mounting clinical data suggests that a large percentage of the hundreds of thousands of bronchoscopies performed every year on suspected lung cancer patients are non-diagnostic—delaying potential lifesaving therapy.